27 Oct 2026, 06:56 IST
Eris Lifesciences Limited
HDFC Securities · BUY · target INR 1,500
The report says Eris's EBITDA grew 7% YoY with sales up 13% YoY, and raised H2FY27 margin guidance to 36%, revising the TP to INR 1,500.
From HSIE Results Daily 27 Oct 26 HSIE, written by HDFC Securities. Orivam summarised it; the view is HDFC Securities's, not Orivam's.
Open the original PDF →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.